{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"2"},{"groupId":"OG003","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"46"}],"units":"Participants"}],"description":"Laboratory abnormality criteria included: HGB; hematocrit; erythrocytes \\< 0.8\\* LLN; erythrocyte mean corpuscular volume/HGB/ HGB concentration, erythrocytes distribution width \\<0.9\\*LLN, \\>1.1\\*upper limit of normal (ULN); platelets \\<0.5\\*LLN,\\>1.75\\* ULN; leukocytes \\<0.6\\*LLN, \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN, \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; activated partial thromboplastin time, prothrombin time \\>1.1\\*ULN; bilirubin\\>1.5\\*ULN; aspartate AT, alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase \\>3.0\\*ULN; protein; albumin\\<0.8\\*LLN, \\>1.2\\*ULN; urea nitrogen, cholesterol, triglycerides \\>1.3\\*ULN; urate \\>1.2\\*ULN; sodium \\<0.95\\*LLN,\\>1.05\\*ULN; potassium, chloride, calcium, magnesium, bicarbonate \\<0.9\\*LLN, \\>1.1\\*ULN; phosphate \\<0.8\\*LLN, \\>1.2\\*ULN; glucose \\<0.6\\*LLN, \\>1.5\\*ULN; creatine kinase \\>2.0\\*ULN.","groups":[{"description":"Participants received placebo matched to tanezumab SC once every 8 weeks for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants in this discontinued treatment arm, received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and completed their treatment before the amendment.","id":"OG001","title":"Tanezumab 10 mg"},{"description":"Participants in this treatment group had received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and after the amendment they continued remaining treatment with tanezumab 20 mg SC once every 8 weeks.","id":"OG002","title":"Tanezumab 10/20 mg"},{"description":"Participants received tanezumab 20 mg SC once every 8 weeks for 24 weeks.","id":"OG003","title":"Tanezumab 20 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set was analyzed. Here, \"Overall Number of Participants Analyzed\" signifies participants with an abnormal baseline with at least one observation of the given laboratory test while on the study. There were no participants in reporting arm \"Tanezumab10/20 mg\", who met the criteria for data collection and analysis of this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1, before dosing) up to Week 48","title":"Number of Participants With Laboratory Abnormalities (Abnormal Baseline)","type":"SECONDARY","unitOfMeasure":"Participants"}